Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology through synthetic lethality. It develops small molecule inhibitors targeting DNA damage response (DDR) pathways, including WEE1 and ATR kinases, to selectively kill cancer cells with specific genetic mutations while minimizing toxicity. Aprea’s pipeline focuses on advanced solid tumors, leveraging integrated discovery platforms to identify novel targets and biomarkers, retaining global rights for development and commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.